The UK and US have established a landmark bilateral deal that will keep zero levies on British pharmaceutical exports going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to raise expenditure on medicines through the NHS. This commitment ensures that duties on these crucial exports will stay at zero for a period of three years.
This deal follows earlier warnings to significantly raise duties on patented pharmaceutical imports, with potential rates discussed up to 100%.
"This deal between the United Kingdom strengthens the global environment for new treatments and brings long-overdue equity to U.S.–U.K. pharmaceutical trade," a release declared.
Commercial Impact
Medicines represent one of the the United Kingdom's biggest exports to the America, which is easily the largest destination for major UK drugmakers.
Statistics show that in the one-year period to the end of last September, the UK exported drugs valued at billions to the US. This value accounted for a significant portion of British export trade in that period.
"This deal secures work, increases capital expenditure and facilitates the UK to become a international leader for life sciences," a government official stated.
Specific British Pledges
The pact includes several specific commitments from the British government:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to double overall health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage drug companies must return to the NHS to stay within budget will be limited at 15%. In the past, refunds were more than 20%.
Recent Tensions
The deal follows a ongoing row between the drug companies and the UK government over drug pricing and approval rates.
The disagreement were exacerbated by assertions that American customers were charged significantly more for the equivalent treatments than people in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had declined as a percentage of its resources over the past decade.
